Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells

Cisplatin has been widely used in the treatment of a various types of cancers including triple-negative breast cancer (TNBC) by damaging DNA and inducing apoptosis. However, its anti-cancer effects are often limited due to chemo-resistance, which is one of the main reasons causing cancer relapse and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shujun, Li, Qun, Lü, Jinhui, Zhao, Qian, Li, Danni, Shen, Lei, Wang, Zhongrui, Liu, Junjun, Xie, Dongping, Cho, William C., Xu, Shaohua, Yu, Zuoren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971202/
https://www.ncbi.nlm.nih.gov/pubmed/32010177
http://dx.doi.org/10.3389/fgene.2019.01278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971202/
https://www.ncbi.nlm.nih.gov/pubmed/32010177
http://dx.doi.org/10.3389/fgene.2019.01278

Ejemplares similares